<unk>  is used to help people stop smoking tobacco (smoking cessation). A meta-analysis found that less than 20% of people treated with<unk>  remain abstinent from smoking at one year. In a 2009 meta-analysis<unk>  was found to be more effective than bupropion (odds ratio 1.40) and nicotine replacement therapies (NRT) (odds ratio 1.56). A 2013 Cochrane overview and network meta-analysis concluded that<unk>  is the most effective medication for tobacco cessation and that smokers were nearly three times more likely to quit tobacco use while on<unk>  than with placebo treatment.<unk>  was more efficacious than bupropion or NRT and as effective as combination NRT for tobacco smoking cessation.<unk>  has not been tested in those under 18 years old or pregnant women and therefore is not recommended for use by these groups.<unk>  is considered a class C pregnancy drug, as animal studies have shown no increased risk of congenital anomalies; however, no data from human studies is available. An observational study is currently being conducted assessing for malformations related to<unk>  exposure, but has no results yet. An alternate drug is preferred for smoking cessation during breastfeeding due to lack of information and based on the animal studies on nicotine.
Varenicline
Seltorexant
Ambulatist
Veristrat
Vernakalant
Suvorexant
Icatibant
Daridorexant